Replimune's RP1 BLA for advanced melanoma gets FDA review, sparking REPL stock surge. Click here to read why REPL stock is ...

When the remnants of Typhoon Halong hit western Alaska this week, radar showed color bands curling across meteorological maps, but people on the ground were already watching what those models ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers.

The Epomaker Luma 84 doesn't live up to expectations as a low-profile mechanical keyboard, with severely lacking support for Mac usage.